CHMP meeting highlights – April 2025
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a variety of new medicines, including several treatments for hereditary and rare conditions.
List view / Grid view
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a variety of new medicines, including several treatments for hereditary and rare conditions.
The global market for growth hormone deficiency (GHD) treatment will rise in value from $1.26 billion in 2014 to reach approximately $1.88 billion by 2024, representing a moderate Compound Annual Growth Rate (CAGR) of 4.08%, according to research and consulting firm GlobalData.